Powered by Business Wire
Biotechnology Headlines

Tetraphase Pharmaceuticals to Present at Upcoming Conferences

JMP Securities Healthcare Conference 2014
2014 BIO International Convention

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced that the company will participate in upcoming scientific and investor conferences.

“New Technologies to Save Us In a Disaster: Opportunities in the Public-Private Partnership to Develop Medical Countermeasures”

Guy Macdonald, Tetraphase President and Chief Executive Officer, will participate in the JMP Securities Healthcare Conference on Wednesday, June 25, at 11:30 a.m. Eastern Time. The conference will take place at the Westin New York Grand Central.

Craig Thompson, Tetraphase Chief Operating Officer, will present at the 2014 BIO International Convention on Wednesday, June 25, at 3:15 p.m. Pacific Time. The presentation will take place in the Pacific Beach Room of the San Diego Convention Center.

Mr. Thompson will also participate in the BIO International Convention session titled “New Technologies to Save Us In a Disaster: Opportunities in the Public-Private Partnership to Develop Medical Countermeasures” on Thursday, June 26 from 2:15 to 3:30 p.m. Pacific Time.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). Under this program, two Phase 3 clinical trials are ongoing: IGNITE 1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE 2 for complicated urinary tract infections (cUTI). Tetraphase has created more than 3,000 novel tetracycline analogs using its technology platform; in addition to eravacycline, Tetraphase has generated multiple preclinical antibiotic candidates that are currently being evaluated for clinical suitability. Please visit www.tphase.com for more company information.


Tetraphase Pharmaceuticals
Jennifer LaVin, 617-715-3591
Argot Partners
Susan Kim, 212-600-1902
Sam Brown Inc.
Mike Beyer, 773-463-4211